NV 27Alternative Names: NV-27
Latest Information Update: 11 Jan 2011
At a glance
- Originator Novogen
- Class Anti-inflammatories; Cardiovascular therapies; Isoflavones
- Mechanism of Action Antioxidants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Coronary artery restenosis